RxDoctor Payments Data

John Price, MD

Family Medicine · Liberty, KYNPI 1558322966

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 85 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$263
  • Novo Nordisk$263
  • Lilly USA, LLC$121
  • AbbVie$106
  • Amgen$87
  • Kowa Pharmaceuticals America, Inc.$84
  • plus $563 from 15 others

What the payments were for

  • Food & beverage$1,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,486 in reported general payments places this provider in the 60th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,733
Medicare patients
42
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$52,779
OzempicSemaglutide48$51,984
JardianceEmpagliflozin30$26,762
MounjaroTirzepatide18$17,727
VascepaIcosapent Ethyl43$17,254
XareltoRivaroxaban16$15,396
Ventolin HfaAlbuterol Sulfate82$4,916
SymbicortBudesonide/Formoterol Fumarate17$4,683
Ondansetron Hcl35$3,280
SynthroidLevothyroxine Sodium40$2,546
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,317
Albuterol Sulfate HfaAlbuterol Sulfate36$1,792
Alprazolam279$1,552
Diclofenac Sodium110$1,358
Lisinopril226$1,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$52,77959 claims
Novo NordiskOzempic$263$51,98448 claims
Lilly USA, LLCMounjaro$121$17,72718 claims
AstraZenecaSymbicort$57$4,68317 claims
AbbVieSynthroid$106$2,54640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Liberty

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →